LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

By |2021-06-22T09:13:46+00:00June 22nd, 2021|News|

Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up

Comments Off on LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
Go to Top